Seqanswers Leaderboard Ad

Collapse

Announcement

Collapse
No announcement yet.
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • Panel Validation using NA12878 DNA

    Hi there,

    we have made a panel that comprises several (190) exonic alterations and now we want to test how capable are we to call these variants starting from a DNA sample. This post is for retrieve suggestions about how can we do this and/or to know if my approach is not correct.

    Basically what I have been thinking about is purchasing NA12878 DNA from Coriell Institute, sequencing it and running a variant calling pipeline (without going into details, mapping vs GRCh37 and call variants with mpileup). Once I have the variants, check them vs the high-confidence calls set focusing on my 190 exonic alterations and if the alleles matches at these positions would mean that we call these variants correctly.

    Is this a correct way?

    Previously, aiming to evaluate just the bioinformatic pipeline and not the laboratory part, I did the same analysis with the GIAB NA12878 dataset (HiSeq x300) and checked the output variants with this callset ftp://ftp.ncbi.nlm.nih.gov/giab/ftp/...ransfer.vcf.gz available at the GIAB ftp site. Previously I normalized the variants representation of both calls sets using *vcflib vcfallelicprimitives*.

    And a last question. For my validation purpose, is there any difference between purchasing the NIST reference DNA and purchasing the Coriell Institute DNA Sample? I think it's the same, but look the difference in prices...

    Any suggestion will be welcome
    Last edited by NielQC; 05-05-2017, 04:00 AM.

Latest Articles

Collapse

  • seqadmin
    Understanding Genetic Influence on Infectious Disease
    by seqadmin




    During the COVID-19 pandemic, scientists observed that while some individuals experienced severe illness when infected with SARS-CoV-2, others were barely affected. These disparities left researchers and clinicians wondering what causes the wide variations in response to viral infections and what role genetics plays.

    Jean-Laurent Casanova, M.D., Ph.D., Professor at Rockefeller University, is a leading expert in this crossover between genetics and infectious...
    Today, 10:59 AM
  • seqadmin
    Addressing Off-Target Effects in CRISPR Technologies
    by seqadmin






    The first FDA-approved CRISPR-based therapy marked the transition of therapeutic gene editing from a dream to reality1. CRISPR technologies have streamlined gene editing, and CRISPR screens have become an important approach for identifying genes involved in disease processes2. This technique introduces targeted mutations across numerous genes, enabling large-scale identification of gene functions, interactions, and pathways3. Identifying the full range...
    08-27-2024, 04:44 AM

ad_right_rmr

Collapse

News

Collapse

Topics Statistics Last Post
Started by seqadmin, 09-06-2024, 08:02 AM
0 responses
13 views
0 likes
Last Post seqadmin  
Started by seqadmin, 09-03-2024, 08:30 AM
0 responses
18 views
0 likes
Last Post seqadmin  
Started by seqadmin, 08-27-2024, 04:40 AM
0 responses
25 views
0 likes
Last Post seqadmin  
Started by seqadmin, 08-22-2024, 05:00 AM
0 responses
387 views
0 likes
Last Post seqadmin  
Working...
X